Ensol Biosciences (XKRX:140610) FCF Margin % : -4,648.12% (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Ensol Biosciences FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Ensol Biosciences's Free Cash Flow for the six months ended in Dec. 2023 was ₩-8,206.0 Mil. Ensol Biosciences's Revenue for the six months ended in Dec. 2023 was ₩176.5 Mil. Therefore, Ensol Biosciences's FCF Margin % for the quarter that ended in Dec. 2023 was -4,648.12%.

As of today, Ensol Biosciences's current FCF Yield % is -11.59%.

The historical rank and industry rank for Ensol Biosciences's FCF Margin % or its related term are showing as below:

XKRX:140610' s FCF Margin % Range Over the Past 10 Years
Min: -4648.12 Med: -941.88 Max: -702.83
Current: -4648.12

During the past 10 years, the highest FCF Margin % of Ensol Biosciences was -702.83%. The lowest was -4648.12%. And the median was -941.88%.

XKRX:140610's FCF Margin % is ranked worse than
87.69% of 1040 companies
in the Biotechnology industry
Industry Median: -139.2 vs XKRX:140610: -4648.12

Ensol Biosciences FCF Margin % Historical Data

The historical data trend for Ensol Biosciences's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ensol Biosciences FCF Margin % Chart

Ensol Biosciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-959.12

-924.64

-2,068.25

-825.67

-4,648.12

Ensol Biosciences Semi-Annual Data
	Dec14	Dec15	Dec16	Dec17	Dec18	Dec19	Dec20	Dec21	Dec22	Dec23
FCF Margin %	Get a 7-Day Free Trial					-959.12	-924.64	-2,068.25	-825.67	-4,648.12

Competitive Comparison of Ensol Biosciences's FCF Margin %

For the Biotechnology subindustry, Ensol Biosciences's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ensol Biosciences's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ensol Biosciences's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Ensol Biosciences's FCF Margin % falls into.

Ensol Biosciences FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Ensol Biosciences's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-8206.032	/	176.545
	=	-4,648.12 %

Ensol Biosciences's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-8206.032	/	176.545
	=	-4,648.12 %

Ensol Biosciences FCF Margin % Related Terms

Thank you for viewing the detailed overview of Ensol Biosciences's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Ensol Biosciences (XKRX:140610) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ensol Biosciences Inc (XKRX:140610) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

51, Techno 10-ro, Yuseong-gu, Daejeon, KOR, 34036

Website

http://www.ensolbio.co.kr

Ensol Biosciences Inc is a Korean big data-driven biopharmaceutical company. The company is engaged in developing drugs for the diseases that have no therapeutic alternatives, such as a degenerative disc, osteoarthritis, cancer, Alzheimer's dementia, and type 1 diabetes. Its drugs portfolio includes Peniel 2000 Drug for Degenerative Disc Disease, Engedi 1000 Drug for Osteoarthritis, Charis 1000 Drug for Immuno-Oncology, Moriah 1000 Drug for Alzheimer's Disease, Shiloah 1000 Drug for Type I Diabetes, and EAD100 Drug for Animal Osteoarthritis.

Ensol Biosciences (XKRX:140610) Headlines

No Headlines